A study recently found that the chronic condition of blood sugar can be controlled more effectively by the use of Tirzepatide or Mounjaro than the use of semaglutide or Ozempic.
The study is slated to be presented at the European Association for the Study of Diabetes (EASD) in early October.
It is a meta-analysis of 22 randomized controlled trials. The theory behind the effectiveness of Tirzepatide was that it mimics the hormone, GLP-1 which is released in response to eating, along with glucose-dependent insulinotropic polypeptide (GIP).
The semaglutide on the other hand can only mimic GLP-1. Thus, the dual action of the drug makes it more effective at controlling the blood sugar.
Moreover, weight loss is also promoted better with the use of Mounjaro as compared to Ozempic. The meta-analysis included studies that tested the drugs in their injectable forms, administered intradermally or given beneath the skin.
Additionally, the meta-analysis found that the direct comparison between the two drugs was only done in two trials. The other 20 trials focused on the comparison between semaglutide or tirzepatide with a common comparator such as an inactive placebo or basal insulin or a GLP-1 agonist drug.
Additionally, the studies were able to provide an indirect comparison between tizepatide and semaglutide. However, the side effects of the drugs were also explored in the analysis along with the added benefit of the weight loss and controlled sugar.
The negative impact of tirzepatide was shown at its highest dose to cause a great risk of vomiting- more than the medium or low doses of semaglutide. Similarly, a great risk of nausea was offered by the drug in comparison to low doses of semaglutide.
The study also concluded that the side effects as well as the cost of the drug may play a role in decision-making of people choosing the drug. The total cost of Mounjaro was $17, 527 in comparison to $22,878 for 68 weeks of semaglutide.